April 12, 2011 09:47 AM Eastern Daylight Time
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Nuvilex, Inc. (OTCQB: NVLX) is pleased to announce the new management team at Nuvilex has made significant inroads into strengthening the Company’s operations and footprint in nutritional supplements.
“We are very excited about our new Marketing and Sales Department. The team has already created a new, simplified environment for direct product sales, energized and expanded purchases, and increased product resellers.”
Present activities include:
- We have formed a Marketing and Sales Department which has created a new, simplified environment for direct product sales, energized and expanded purchases, and increased resellers.
- Tighter and higher efficiency integration in manufacturing, marketing, distribution, sales and pricing has resulted in increased revenue.
- The Company’s plans are on track to release new packaging and sizes for Cinnergen and other existing products.
- The Company is planning to offer new products by the second half of 2011.
- Restructured pricing has enhanced gross profit margins.
Dr. Robert Ryan, President and CEO of Nuvilex commented, “Our Board Chairman and Co-Founder, Mrs. Patricia Gruden and COO, Dr. Gerald Crabtree, have solidified the company’s potential. This has occurred through methodical, responsible planning and management allowing expansion of revenue and reduction of operating costs. We are also producing new offerings for glucose, cholesterol, normal and damaged skin management.”
Dr. Ryan also stated, “We are very excited about our new Marketing and Sales Department. The team has already created a new, simplified environment for direct product sales, energized and expanded purchases, and increased product resellers.”
Board Chairman, Mrs. Patricia Gruden commented, “I am excited by effort and energy put forward by our team. With the level of commitment and energy expended by Drs. Ryan, Crabtree and our new Marketing and Sales Department, we have realized an increase in revenue and opportunities. This leads me to anticipate solid growth of Nuvilex as our fiscal year draws to a close and we start a new year with a great outlook together.”
We at Nuvilex, Inc. are…
a Green Company specializing in multiple areas that are: “Good for you and Good for the environment,” including biotechnology development and natural products. The Company’s current products include Cinnergen™, promotes a healthy glucose metabolism; Cinnechol™, balances triglycerides and supports cardiovascular function; Cinnsational™ (previously last Shot™), decreases detrimental effects of alcohol ingestion in alcohol-sensitive individuals; Talsyn™, a unique, barrier-creating, plant and lipid-peptide combination product used for the management of keloids, hypertrophic scars, erythema and surgical incisions; NumaDerm™, healthy, natural cosmetic products; Citroxin™, safe, non-toxic, natural product line capable of killing bacteria, viruses, and fungi, including avian flu and MRSA (methicillin-resistant Staphylococcus aureus); Oraphyte™, a natural nematocide product line, effective in combating nematodes harmful to grass and plant growth; Reme-Flu™, manufactured by Legacy Biotechnologies, Inc., a unique, two-part homeopathic medicine for treating flu symptoms; and Virgin® and Infinitink®, heavy-metal-free, tattoo inks.
For more information, please visit our website www.nuvilex.com. Shareholders and all persons interested in monitoring the progress of our company as we move forward are encouraged to subscribe to the electronic mailing list by submitting their email address to email@example.com.
Safe Harbor Statement
This information may contain forward-looking statements that involve risks and uncertainties. Actual results, events and performances could vary materially from those contemplated by these forward-looking statements. These statements involve known and unknown risks and uncertainties which may cause the Company’s actual results, expressed or implied, to differ materially from expected results. These risks and uncertainties include, among other things, product demand, market competition, and the Company’s inability to obtain financing to meet current or future plans. You should independently investigate and fully understand all risks before making an investment decision. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. The Company does not undertake any obligation to publicly release revisions to any forward-looking statement, to reflect events or circumstances after the date of this presentation, or to reflect the occurrence of unanticipated events, except as is required under applicable securities laws.